On the fourth and final day of the American Society of Hematology (ASH) 2011 annual meeting, there was one session in the morning with a number of important myeloma-related presentations.

The key findings of those presentations are summarized in this article.

Treatment Of High-Risk Smoldering Myeloma

Dr. María-Victoria Mateos from the University Hospital in Salamanca, Spain, kicked off the session.

She gave a presentation reviewing a Phase 3 trial she and her colleagues are conducting on the treatment of high-risk smoldering myeloma patients with Revlimid (lenalidomide) and dexamethasone…

As the third day of the 2011 American Society of Hematology (ASH) annual meeting came to an end, attendees could look back on an agenda that featured presentations about a wide range of potential new myeloma therapies.

The afternoon myeloma sessions were focused, in fact, on potential new therapies.

The Beacon’s previous ASH 2011 update covered the afternoon presentations about carfilzomib and pomalidomide, two potential myeloma therapies that are in the late stages of development.

This update covers the afternoon’s presentations about four other potential new myeloma therapies —…

The afternoon sessions of the third day of the American Society of Hematology (ASH) 2011 annual meeting in San Diego were just as awash with myeloma-related presentations as were the morning sessions.

Many of the afternoon sessions were devoted to two particular potential new myeloma treatments: carfilzomib and pomalidome.

Those presentations will be covered in this article, while presentation from the afternoon sessions that were about other new therapies will be summarized in the final daily update for the meeting’s third day.

Carfilzomib

Carfilzomib is an investigational drug that belongs…

Yesterday, the third day of the American Society of Hematology (ASH) 2011 Annual Meeting in San Diego, was the busiest day of the meeting for people interested in multiple myeloma.  Myeloma-related presentations filled the entire morning and afternoon, and sometimes there were even multiple relevant presentations going on simultaneously.

The morning presentations about therapies combining current myeloma drugs will be covered in this update.  Morning presentations about potential new myeloma therapies were covered in an update published earlier today, and presentations from the rest of the day will be…

Yesterday was the third day of the American Society of Hematology (ASH) 2011 Annual Meeting in San Diego, and it was packed full with multiple myeloma-related presentations. Presentations started early in the morning and continued through the afternoon.

The morning presentations about potential new myeloma therapies will be covered in this update, and presentations from the rest of the day will be covered in additional updates.

MLN9708

During the first talk of the day, Dr. Paul Richardson from the Dana-Farber Cancer Institute in Boston presented results from a Phase 1…